相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients
Ekaterina Y. Tsareva et al.
PHARMACOGENOMICS (2012)
Current and emerging therapies in multiple sclerosis: a systematic review
Wanda Castro-Borrero et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2012)
Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy
Nadja Borisow et al.
EPMA JOURNAL (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Apolipoprotein Alleles and the Response to Interferon-beta-1b in Multiple Sclerosis
Olga Carmona et al.
EUROPEAN NEUROLOGY (2011)
Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis
A. L. Guerrero et al.
NEUROLOGIA (2011)
Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis
P. Serrano-Fernandez et al.
AUTOIMMUNITY (2010)
Multiple sclerosis: a practical overview for clinicians
Konrad Rejdak et al.
BRITISH MEDICAL BULLETIN (2010)
Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis
Rachel A. Farrell et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2010)
Natalizumab treatment reduces endothelial activity in MS patients
Alban Millonig et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Oral therapies for multiple sclerosis: are we there yet?
Hans-Peter Hartung et al.
LANCET NEUROLOGY (2010)
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
J. Mellergard et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients
Christian Enevold et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Multiple sclerosis pharmacogenomics Maximizing efficacy of therapy
Derek J. Pappas et al.
NEUROLOGY (2010)
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
M. Mehling et al.
NEUROLOGY (2010)
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS
Robert H. Goertsches et al.
PHARMACOGENOMICS (2010)
Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands
Toshiyuki Tsunoda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis
Manuel Comabella et al.
ARCHIVES OF NEUROLOGY (2009)
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis
S. Cotte et al.
BRAIN (2009)
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Volker Brinkmann
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients
A. N. Al-Masri et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Glypican 5 is an interferon-beta response gene: a replication study
M. D. C. Cenit et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
New oral drugs for multiple sclerosis
Claudio Gasperini et al.
NEUROLOGICAL SCIENCES (2009)
Genome-wide pharmacogenomic analysis of the response to interferon β therapy in multiple sclerosis
Esther Byun et al.
ARCHIVES OF NEUROLOGY (2008)
GTPase activity is not essential for the interferon-inducible MxA protein to inhibit the replication of hepatitis B virus
Zhijian Yu et al.
ARCHIVES OF VIROLOGY (2008)
Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis
Elke Wiesemann et al.
CLINICAL IMMUNOLOGY (2008)
Biological response genes after single dose administration of interferon β-1b to healthy male volunteers
Jan Hilpert et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients
Bianca Weinstock-Guttman et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Modulation of IFNAR1 mRNA expression in multiple sclerosis patients
Federico Serana et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
Raija L. P. Lindberg et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Glatiramer acetate - Evidence for a dual mechanism of action
Francois Blanchette et al.
JOURNAL OF NEUROLOGY (2008)
Pharmacogenomics of Interferon-β Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
Lisa G. M. van Baarsen et al.
PLOS ONE (2008)
Interferons at age 50: past, current and future impact on biomedicine
Ernest C. Borden et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Immunosuppressive agents in multiple sclerosis
Oliver Neuhaus et al.
NEUROTHERAPEUTICS (2007)
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
Iris Grossman et al.
PHARMACOGENETICS AND GENOMICS (2007)
Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis
R. M. Valenzuela et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
Interferon receptor expression in multiple sclerosis patients
Begona Oliver et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
IFN-β-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia
Hongwei Qin et al.
FASEB JOURNAL (2006)
Heparan sulfate proteoglycans and the emergence of neuronal connectivity
D Van Vactor et al.
CURRENT OPINION IN NEUROBIOLOGY (2006)
Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients
J Río et al.
ANNALS OF NEUROLOGY (2006)
A homeodomain-zinc finger protein, ZFHX4, is expressed in neuronal differentiation manner and suppressed in muscle differentiation manner
Kazunori Hemmi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2006)
Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis:: A genetic screen of 100 type I interferon-inducible genes
S Cunningham et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
L Leyva et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis
S Wergeland et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Pharmacogenetics of autoimmune diseases: Research issues in the case of Multiple Sclerosis and the role of IFN-beta
F Macciardi et al.
JOURNAL OF AUTOIMMUNITY (2005)
The ABC transporter structure and mechanism: perspectives on recent research
PM Jones et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis
HJ Kim et al.
JOURNAL OF IMMUNOLOGY (2004)
Defining interferon β response status in multiple sclerosis patients
RA Rudick et al.
ANNALS OF NEUROLOGY (2004)
Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis
A Petzold et al.
MULTIPLE SCLEROSIS JOURNAL (2004)
Genomic effects of IFN-β in multiple sclerosis patients
B Weinstock-Guttman et al.
JOURNAL OF IMMUNOLOGY (2003)
Clinical characteristics of responders to interferon therapy for relapsing MS
E Waubant et al.
NEUROLOGY (2003)
Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis
S Stürzebecher et al.
BRAIN (2003)
Expression of the interferon-induced MxA protein in viral encephalitis
JB Lampe et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2003)
Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis
U Sriram et al.
GENES AND IMMUNITY (2003)
Interferon β-1a in primary progressive MS -: An exploratory, randomized, controlled trial
SM Leary et al.
NEUROLOGY (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy
M Trojano et al.
MULTIPLE SCLEROSIS JOURNAL (2003)
Immunomodulatory agents for the treatment of relapsing multiple sclerosis
SL Galetta et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS
D Brassat et al.
NEUROLOGY (2002)
The interferon-α/β system in antiviral responses:: a multimodal machinery of gene regulation by the IRF family of transcription factors
T Taniguchi et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α2b vs. IFN-β1a:: Understanding the functional relationship between distinct type I interferons that act through a common receptor
AJ da Silva et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2002)
HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis
C Fusco et al.
NEUROLOGY (2001)
Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS
A Kracke et al.
NEUROLOGY (2000)
分享论文
